Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year
Executive Summary
Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.
You may also be interested in...
New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset
Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.
GSK’s Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow
Arexvy will launch in the US in time for the fall 2023 RSV season for adults 60 and older, GSK said. Pfizer’s Abrysvo is also pending at the FDA.